← back to search

Christine E. Engeland

University Hospital Leipzig ·
Area of research
Genetics · Oncology
Research interest
Research interests include Virus-based gene therapy research, CAR-T cell therapy research, Cancer Research and Treatments, and Virology and Viral Diseases.
h-index
22
citations
1,523
works
73
NIH funding
primary concept
email

Recent publications

Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures
EBioMedicine 2024cited by 23position: lastdoi
A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
Cell Death and Disease 2023cited by 9position: lastdoi
Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference
Viruses 2023cited by 8position: middledoi
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
Frontiers in Immunology 2023cited by 5position: lastdoi
Advances in oncolytic virotherapy
Communications Medicine 2022cited by 31position: middledoi
Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine
Molecular Therapy — Methods & Clinical Development 2022cited by 3position: firstdoi
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Journal of Hematology & Oncology 2021cited by 101position: lastdoi
Measles Virus as an Oncolytic Immunotherapy
Cancers 2021cited by 90position: firstdoi
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Cancer Research 2021cited by 41position: middledoi
Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Viruses 2021cited by 31position: middledoi
MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer
Molecular Therapy — Oncolytics 2021cited by 23position: middledoi
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
Molecular Therapy — Oncolytics 2021cited by 18position: lastdoi
Mechanisms of measles virus oncolytic immunotherapy
Cytokine & Growth Factor Reviews 2020cited by 52position: lastdoi
Measles Vaccines Designed for Enhanced CD8+ T Cell Activation
Viruses 2020cited by 18position: lastdoi
Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations
Journal of General Virology 2020cited by 9position: middledoi
Re: “Oncolytic Measles Virus Encoding Interleukin-12 Mediated Antitumor Activity and Immunologic Control of Colon Cancer <i>In Vivo</i> and <i>Ex Vivo</i> ” by Wang et al.
Cancer Biotherapy and Radiopharmaceuticals 2020cited by 1position: firstdoi
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Frontiers in Oncology 2019cited by 58position: middledoi
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
Viruses 2019cited by 43position: lastdoi
Introduction to Oncolytic Virotherapy
Methods in molecular biology 2019cited by 31position: firstdoi
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Journal of Visualized Experiments 2019cited by 16position: lastdoi
Mathematical Modeling of Oncolytic Virotherapy
Methods in molecular biology 2019cited by 13position: middledoi
Immunomodulation in Oncolytic Measles Virotherapy
Methods in molecular biology 2019cited by 10position: lastdoi
Oncolytic Viruses
Methods in molecular biology 2019cited by 7position: firstdoi
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Journal of Visualized Experiments 2019cited by 4position: lastdoi
Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites
Molecular Therapy — Oncolytics 2018cited by 38position: middledoi
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation
OncoImmunology 2017cited by 77position: lastdoi
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
BMC Cancer 2017cited by 44position: middledoi
Fighting Cancer with Mathematics and Viruses
Viruses 2017cited by 31position: middledoi
Virotherapy Research in Germany: From Engineering to Translation
Human Gene Therapy 2017cited by 23position: middledoi
A Tupaia paramyxovirus vector system for targeting and transgene expression
Journal of General Virology 2017cited by 10position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Guy Ungerechts · German Cancer Research Center20 papers (2014–2023)Dirk Jäger · German Cancer Research Center16 papers (2014–2023)Christof von Kalle · Luxembourg Institute of Health8 papers (2014–2021)Rūta Veinalde · Heidelberg University8 papers (2014–2023)Johannes P.W. Heidbuechel · German Cancer Research Center7 papers (2017–2021)Mathias F. Leber · German Cancer Research Center6 papers (2014–2023)Sascha Bossow · German Cancer Research Center6 papers (2014–2021)Christoph Springfeld · Université Grenoble Alpes6 papers (2017–2021)Christian Grossardt · German Cancer Research Center6 papers (2014–2021)Birgit Hoyler · German Cancer Research Center5 papers (2017–2020)John C. Bell · University of Florida5 papers (2017–2022)Jessica Albert · Seattle University4 papers (2014–2020)Gemma Pidelaserra-Martí · Witten/Herdecke University4 papers (2020–2023)Christian J. Buchholz · Goethe University Frankfurt3 papers (2017–2021)Jean Rommelaere · German Cancer Research Center3 papers (2017–2021)Heiko Enderling · Dartmouth College3 papers (2017–2019)Daniel Abate‐Daga · Moffitt Cancer Center3 papers (2017–2019)Hans Martin Singh · German Cancer Research Center3 papers (2014–2021) · 2 papers (2016–2017)Lara M. Jeworowski · Humboldt-Universität zu Berlin2 papers (2019–2021)